Abstract: The present invention relates to a new type of solid balneological preparations for cosmetic, hygienic and therapeutic use, which has both the properties of a solid bath additive and those of liquid products, and is characterized especially by the addition of lipid components, vesicle forming lipids, tensides and, in some cases, mineral salts. Active components, adjuvants such as stabilizers, adsorbing substances, lubricants as well as smoothing and breakdown promoting agents may also be contained therein.

Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.

Abstract: Certain 1-aminoalkylcyclohexanes are systemically-active uncompetitive NMDA receptor antagonists having rapid blocking/unblocking kinetics and strong voltage-dependency and are therefore useful in the alleviation of conditions resulting from disturbances of glutamatergic transmission giving them a wide range of utility in the treatment of CNS disorders involving the same, as well as in non-NMDA indications, due to their immunomodulatory, antimalarial, anti-Borna virus, and anti-Hepatitis C activities and utilities. Pharmaceutical compositions thereof and a method-of-treating conditions which are alleviated by the employment of an NMDA receptor antagonist, as well as the aforementioned non-NMDA indications, and a method for the preparation of the active 1-aminoalkylcyclohexane compounds involved.

Abstract: An adjustable amount of liquid is reproducibly withdrawn from a container having a pre-chamber in free flow communication with the interior of the container. The pre-chamber is initially filled with an amount of liquid from the container and is in communication with a measuring chamber. The measuring chamber has an adjustably pre-set volume and is in communication with a closeable outlet. Thus, after the amount to be withdrawn from the measuring chamber has been adjusted, discharge of the preset volume is effected through the outlet without the necessity of additional manipulations such as shaking the container or separating the dosage metering part from the container to effect the discharge of a precise amount of liquid.

Abstract: Pyridyl-phtalazin diones having the following formula: ##STR1## wherein R1 and R2 are selected from the group consisting of hydrogen, halogen, and methoxy or wherein R1 and R2 together form methylenedioxy, and pharmaceutically-acceptable salts thereof, and pharmaceutical compositions containing an effective glycine.sub.B antagonistic amount thereof, are useful in combatting neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission in a living animal, including a human, in need thereof.

Abstract: The invention relates to novel essentially anhydrous oily bath and shower compositions containing a combination of fatty oil and/or fatty or waxy apolar substance, oil-soluble surfactant, and vesicle-forming lipid and, if desired, a cosmetically- or balneologically-active ingredient. When poured into or simply admixed with water, these formulations immediately and automatically, generate dispersed vesicles or liposomes. They exhibit an immediate as well as a prolonged or depot effect, can be used alone or added to or together with existing bath or shower formulations, and are especially suited for use in connection with or as additives to full, partial, or shower baths.

Abstract: The invention relates to liposome preparations with controllable vesicle size and type between about 20 and 150 nm and high stability without increased permeability, the vesicle membrane of the liposomes consisting essentially of lecithin and 10%-90%, preferably 16-90%, and most especially 20-80%, of a specified fatty acid-esterified collagen hydrolysate (FAECH), namely, a fatty acid ester of a lipoaminoacid or lipopeptide, representatively OHAP, plus traditional jellifying agents, adjuvants, and pharmaceutical agents as desired, and the production and use thereof in cosmetic and pharmaceutical compositions, as well as a method of controlling vesicle dimensions and reducing vesicle particle size by employing increased and previously believed inoperative ratios of FAECH to lecithin.

Abstract: The present invention provides solid pharmaceutical compositions in dosage form containing an active ingredient or principle, preferably memantine, which exhibit an extended two-phase release profile and which are characterized by the presence of both a water-soluble and a water-insoluble salt of casein, preferably sodium and calcium caseinate, in the matrix thereof, in broad proportions and in a total amount between 5 and 98% by weight of the composition, and with a process for the production thereof.

Abstract: The application discloses a process for the manufacture of mechanically-stable, readily-disintegratable tablets made of small preformed, preferably rounded, particles or pellets containing a high percentage of active ingredient in which--prior to compression--the particles are coated with an aqueous or aqueous/organic suspension containing water-soluble polyvinyl alcohol having an ester content of 19.4 to 6.7%, a disintegrant, and finely-divided cellulose, the remainder being excipients such as additional colloids, adjuvants, dyes, and/or flavors and the suspending liquid, and dried, the stable but readily-friable tablet product thus-produced, and a method of delivering an active ingredient by the employment of such a tablet for oral ingestion.

Abstract: The use of an effective monoamine oxidase-inhibitory amount or portion of black currant juice (Ribes nigrum L.) or concentrate or dry extract thereof to activate the brain and central nervous system, in a living animal, especially a human being, in need thereof, and thereby to increase the general cerebral performance, especially in healthy and elderly people, and for the prevention, treatment, and alleviation of neurodegenerative diseases associated with reduced cerebral performance, such as Parkinson's disease, dementia, and mood disorders, and compositions thereof for such purpose, are disclosed.

Abstract: Pharmaceutically-active BHT-omega pyridyl ethers of the formula selected from BHT-omega-pyridyl ether compounds of the formula: ##STR1## wherein m=1,3for m=1, .SIGMA.=6-9for m=3, .SIGMA.=5-11Sum (.SIGMA.)=[m+n+1 (for oxygen)]wherein the bond between the two carbon atoms of the (CH.sub.2).sub.n moiety most closely adjacent the pyridine ring is a single, double, or triple bond, and pharmaceutically-acceptable acid addition salts thereof, pharmaceutical compositions thereof, and a method of combating lipidemia and atherosclerosis therewith, are disclosed.

Abstract: The antitumor and antiviral compound avarone, a process for its production, pharmaceutical compositions containing said compound, and a method of combating susceptible viruses and tumors therewith, are disclosed.

Abstract: A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms;whereinR.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl;whereinR.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group,or a pharmaceutically-acceptable salt thereof, is disclosed.

Abstract: The invention concerns the use of avarone and pharmaceutical compositions thereof for the control of AIDS and AIDS-Related Complex (ARC).

Abstract: The invention concerns the use of avarone and pharmaceutical compositions thereof for the control of adult T-cell leukemia/lymphoma.

Abstract: Novel antitumor and antiviral xanthate compounds, a process for their production, pharmaceutical compositions containing said xanthate compounds, and a method of combating viruses and tumors therewith, are disclosed.

Abstract: The antiviral compond avarol, a process for its production, pharmaceutical compositions containing said compound, and a method of combating viruses therewith, are disclosed.

Abstract: The invention concerns the use of avarol and its derivatives and pharmaceutical compositions thereof for the control of AIDS and AIDS-related Complex (ARC).

Abstract: The invention concerns the use of avarol and its derivatives and pharmaceutical compositions thereof for the control of adult T-cell leukemia/lymphoma.

Abstract: The invention refers to antiviral and antitumor compositions which are useful for the control of viruses and tumors and which, in addition to a known antiviral or antitumor active xanthate, contain an adjuvant which increases its antiviral and antitumor action. The adjuvant is an ionic, preferably an anionic, compound with a lipophilic group and a hydrophilic group, preferably an alkali metal deoxycholate or a compound the lipophilic moiety of which is a straight or branched, saturated or unsaturated, aliphatic group with six to eighteen carbon atoms, and the hydrophilic group of which has one or two carboxyl, sulphate, sulphonate, or phosphate groups, or a pharmaceutically-acceptable salt thereof.